Search PubMed⌕ Search

Biomedical subjects

R H Roth

Publications and source records attributed to R H Roth.

At least 199 records · Page 11Linked to original sources

The localization and characterization of substance P and substance K in striatonigral neurons.

Specific substance P and substance K radioimmunoassays coupled to high-performance liquid chromatography were used to characterize striatal and nigral tachykinin immunoreactivity. Using these assays, authentic substance P and substance K accounted for nearly all substance P and substance K immunoreactivity, respectively. A series of coronal knife cuts of the striatum caused parallel depletions in nigral substance P and substance K, consistent with the possible colocalization of these tachykinins in striatonigral neurons.

Animals↗

Activation of the locus coeruleus induced by selective stimulation of the ventral tegmental area.

The effects of selective stimulation of perikarya, but not axons of passage, within the ventral tegmental area (VTA) on the locus coeruleus (LC) noradrenergic system were examined. Anterograde and combined retrograde-immunohistochemical studies indicated both dopaminergic and non-dopaminergic projections to the region of the LC originating from the VTA. Kainic acid (KA) stimulation of the VTA resulted in a dose-dependent increase in the levels of the dopamine metabolite dihydroxyphenylacetic acid (DOPAC) in the prefrontal cortex, and also elevated levels of the norepinephrine (NE) metabolite 3-methoxy-4-hydroxyphenolglycol (MHPG). Prefrontal cortical MHPG levels did not increase in response to vehicle injection or KA infusion into the hippocampus, nor did concentrations of this metabolite increase in the prefrontal cortex in response to intra-VTA KA in animals with neurotoxic lesions of the VTA. KA injection into the VTA resulted in increased MHPG levels in the hippocampus, but not the hypothalamus. Dorsal noradrenergic bundle knife cuts prevented the KA-elicited prefrontal cortical MHPG increase. These data suggest that stimulation of the mesocoeruleo dopaminergic projection arising from the VTA results in selective excitation of the LC-derived dorsal bundle noradrenergic system.

Animals↗

Survival and growth of fetal catecholamine neurons transplanted into primate brain.

Dopamine and norepinephrine neuroblasts of the ventral mesencephalon, hypothalamus, and dorsolateral pons were transplanted from fetal African green monkeys into multiple brain sites in adult (host) African green monkeys. Tissue was grafted from both early and late gestational age fetuses. Immunohistochemical analysis, with antibodies to tyrosine hydroxylase, a marker of catecholamine-containing neurons, showed large numbers of transplanted catecholamine neurons in host cerebral cortex, corpus striatum and lateral ventricles up to 69 days after transplantation. Serial reconstructions revealed extensive outgrowth of neuronal processes from large numbers of transplanted neurons as well as expansion of the size of transplanted (solid) grafts of fetal brain tissue in the host brain. Some grafts extended from the caudate nucleus into the adjacent lateral ventricles or from the cerebral cortex into the underlying corpus callosum and ventricle. There were dense networks of varicose fibers emanating from the tyrosine hydroxylase positive neurons within intraparenchymal and intraventricular grafts. The size and shape of transplanted neurons retained characteristics common to catecholaminergic neurons from the dissected regions of fetal brain. Thus, a variety of fetal, catecholamine-containing neurons survive transplantation to primate brain and produce extensive neuritic outgrowths. Moreover, rejection of transplanted tissue was not apparent. These findings provide essential information on nerve cell grafting in a species closely related to humans as a prerequisite in the consideration of neural transplants as therapeutic measures in neurological disease.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗

Circadian rhythms in catecholamine metabolites and cyclic nucleotide production.

Circadian rhythms in noradrenergic (NE) and dopaminergic (DA) metabolites and in cyclic nucleotide production were measured in discrete regions of rat brain. A circadian rhythm was found in the concentration of the NE metabolite, 3-methoxy-4-hydroxyphenylglycol (MHPG), in the hippocampus. No MHPG rhythm was found in frontal, cingulate, parietal, piriform, insular or temporal cortex, or in hypothalamus. Circadian rhythms in the concentration of the NE metabolite, 3,4-dihydroxyphenylglycol (DHPG), occurred in occipital and parietal cortex and hypothalamus, with no rhythm observable in temporal or insular cortex, hippocampus, pons-medulla or cerebellum. The 24-hr mean concentration of MHPG varied 3.5-fold, highest in cingulate and lowest in parietal, temporal and occipital cortex. The 24-hr mean concentration of DHPG varied 6-fold, highest in hypothalamus and lowest in parietal cortex. Circadian rhythms in the concentration of the DA metabolite, homovanillic acid (HVA), were found in olfactory tubercle, amygdala and caudate-putamen, but not in nucleus accumbens. A circadian rhythm in the concentration of the DA metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), occurred in nucleus accumbens, but not in olfactory tubercle or caudate-putamen. The mean 24-hr concentration of HVA was highest in caudate-putamen, intermediate in nucleus accumbens, and lowest in olfactory tubercle and amygdala. The mean 24-hr concentration of DOPAC was highest in nucleus accumbens and lower in olfactory tubercle and caudate-putamen. Circadian rhythms were found in the concentration of cyclic GMP (cGMP) in all regions measured except parietal cortex. The mean 24-hr concentration varied 128-fold, highest in nucleus accumbens, frontal poles, and hypothalamus and lowest in cingulate cortex. Circadian rhythms in cyclic AMP (cAMP) concentration were found in piriform, temporal, occipital, cingulate, and parietal cortex, amygdala and nucleus accumbens. No rhythms were found in frontal or insular cortex, hypothalamus, hippocampus, caudate-putamen or olfactory tubercle. The 24-hr mean cAMP concentration varied 4-fold, highest in parietal cortex and lowest in caudate-putamen and amygdala. Norepinephrine metabolites and dopamine metabolites were rhythmic in few regions. It is, therefore, unlikely that the rhythmicity measured in adrenergic receptors is, in general, a response to rhythmic changes in adrenergic transmitter release. The putative second messenger response systems, especially cGMP, were more often rhythmic. The rhythms in cGMP are parallel in form and region to those in the alpha 1-adrenergic receptor and may act as 2nd messenger for that receptor.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

Relationships between behavioral rhythms, plasma corticosterone and hypothalamic circadian rhythms.

Circadian rhythms in physiological processes and behaviors were compared with hypothalamic circadian rhythms in norepinephrine (NE) metabolites, adrenergic transmitter receptors, cAMP, cGMP and suprachiasmatic nucleus (SCN) arginine vasopressin (AVP) in a single population of rats under D:D conditions. Eating, drinking and locomotor activity were high during the subjective night (the time when lights were out in L:D) and low during the subjective day (the time when lights were on in L:D). Plasma corticosterone concentration rose at subjective dusk and remained high until subjective dawn. Binding to hypothalamic alpha 1- and beta-adrenergic receptors also peaked during the subjective night. Cyclic cGMP concentration was elevated throughout the 24-hr period except for a trough at dusk, whereas DHPG concentration peaked at dawn. Arginine vasopressin levels in the suprachiasmatic nucleus peaked in the middle of the day. No rhythm was found either in binding to the alpha 2-adrenergic receptor, or in MHPG or cAMP concentration. Behavioral and corticosterone rhythms, therefore, are parallel to rhythms in hypothalamic alpha 1- and beta-receptor binding and NE-release. Cyclic GMP falls only at dusk, suggesting the possibility that cGMP inhibits activity much of the day and that at dusk the inhibition of nocturnal activity is removed. SCN AVP, on the other hand, peaking at 1400 hr, may play a role in the pacemaking function of the SCN that drives these other rhythms.

Animals↗

Regulation of dopamine synthesis in the medial prefrontal cortex: studies in brain slices.

The rapid firing rates and small dopamine (DA) pools that characterize mesoprefrontal DA neurons make these cells more vulnerable to release-dependent changes in intraneuronal DA levels than nigrostriatal DA neurons. In vivo studies of mesoprefrontal DA synthesis are therefore complicated by the necessity to distinguish between effects of dopaminergic drugs on synthesis-modulating autoreceptors and effects resulting from increased end product inhibition of tyrosine hydroxylase (TH) secondary to decreased DA release. We have used brain slices, in which impulse flow-dependent release is apparently attenuated, to compare regulation of tyrosine hydroxylation in striatal and prefrontal nerve terminals. Accumulation of DOPA after decarboxylase inhibition was used as an index of TH activity. Nomifensine, a DA uptake blocker, inhibited DOPA synthesis in striatal but not prefrontal slices. This effect was reversed stereoselectively by sulpiride, suggesting it involved activation of DA receptors by elevated synaptic levels of DA. DOPA synthesis was stimulated in both brain regions by elevated K+; however, only striatal synthesis could be further enhanced by sulpiride. This enhancement was dose dependent, stereoselective and significantly attenuated by EMD 23 448, a putative autoreceptor-selective DA agonist that does not exert direct inhibitory effects on TH activity in vitro. EMD 23 448 had no effect on prefrontal slices at concentrations that produce greater than 50% inhibition of striatal DOPA synthesis. These findings suggest: released DA modulates TH activity in striatal slices via a receptor-mediated mechanism, independent of end product inhibitory effects.(ABSTRACT TRUNCATED AT 250 WORDS)

4-Butyrolactone↗

Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo.

Previous studies have suggested that rat mesoprefrontal dopamine (DA) neurons are devoid of synthesis and impulse-modulating autoreceptors. We have examined further the presynaptic regulatory parameters of these neurons in vivo and have developed a model based on the following observations. Prefrontal DA turnover, measured as the rate of DA disappearance after inhibition of tyrosine-3-monooxygenase by alpha-methyltyrosine, is relatively rapid (T1/2 = 15 min) and is suppressed by apomorphine (50 micrograms/kg) pretreatment, suggesting that prefrontal DA release is sensitive to regulation by DA agonists. Prefrontal DOPA accumulation (measured after inhibition of decarboxylase with m-hydroxybenzylamine) is also diminished after administration of DA agonists, such as apomorphine, BHT-920, 3-[4-(4-phenyl)-1,2,3,6-tetrahydropyridyl-1] butyl indole (EMD 23 448) and 3-(3-hydroxyphenyl)-N-n-propylpiperidine[(+)-3-PPP]. However, the apomorphine-induced inhibition of prefrontal, but not striatal, DOPA synthesis is blocked by either cessation of impulse-dependent DA release (after gamma-butyrolactone) or by depletion of intraneuronal DA (after reserpine), suggesting that DA agonists affect prefrontal DA synthesis only in the presence of DA release. Inhibition of impulse flow after administration of gamma-butyrolactone does not increase the rate of prefrontal tyrosine hydroxylation in vivo, suggesting that synaptic DA does not influence medial prefrontal DA synthesis under basal conditions. After treatment with m-hydroxybenzylamine (30 min), prefrontal DA levels are substantially reduced (-70%) and inhibition of prefrontal synthesis by DA agonists is associated with an increase in intraneuronal DA relative to m-hydroxybenzylamine-treated controls, suggesting that agonist-induced synthesis inhibition is a consequence of activation of release-modulating autoreceptors with a subsequent decrease in DA release and increase in end product inhibition of tyrosine hydroxylation. These and other data in the accompanying paper suggest that the nerve terminals of mesoprefrontal DA neurons are unique in their constitution of functional autoreceptors in that they contain only a release-modulating mechanism.

3,4-Dihydroxyphenylacetic Acid↗

Substance K and substance P in the ventral tegmental area.

A comparison was made between substance P (SP) and substance K (SK) in the ventral tegmental area (VTA) (A10 dopamine cell group) of the rat. Approximately equal densities of SP and SK-immunoreactive neuronal fibers were observed. However, while previous reports demonstrate negligible density of autoradiographically defined SP receptors in the VTA, we observed a high density of SK receptors. SK or SP was microinjected into the VTA, and changes in spontaneous motor activity were measured using a photocell apparatus. SK was found to be at least 10 times more potent than SP in producing an increase in motor activity. These data suggest that while both SK and SP are present in the VTA, SK may have a more significant physiological role in modulating dopamine neurons in the ventromedial mesencephalon.

Animals↗

Footshock and conditioned stress increase 3,4-dihydroxyphenylacetic acid (DOPAC) in the ventral tegmental area but not substantia nigra.

The effects of stress on dopamine (DA) metabolism in the mesencephalic DA cell body areas and DA terminal field regions were examined. Both mild footshock stress and exposure to a neutral stimulus previously paired with footshock resulted in a selective increase in the levels of the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in the prefrontal cortex as has been previously reported. Footshock stress also resulted in a slight but significant increase in DOPAC levels in the olfactory tubercles. DOPAC levels were selectively increased in the A10 cell body area (ventral tegmental area) but not A9 region (substantia nigra) by both footshock and the conditioned stress paradigm. These data indicate that the cell bodies of origin of the mesocortical dopaminergic system are activated by stress in contrast to those DA neurons innervating the striatum. It appears that mesocortical dopaminergic neurons exhibit different regulatory features than mesolimbic or nigrostriatal neurons.

3,4-Dihydroxyphenylacetic Acid↗

Precipitated diazepam withdrawal elevates noradrenergic metabolism in primate brain.

Following treatment for seven days with diazepam (2.0 mg/kg i.m., b.i.d.), administration of the benzodiazepine receptor antagonist RO 15-1788 (5 mg/kg) induced a severe withdrawal syndrome in vervet monkeys which included tremors, vomiting, vocalizations, chewing, and piloerection. Brain concentrations of the noradrenergic metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) were significantly higher in the precipitated withdrawal group than in the diazepam plus vehicle control group. Administration of RO 15-1788 without prior diazepam treatment had no effect on brain MHPG, nor did it produce withdrawal behaviors, but did produce an increase in the frequency of scratching. These results raise the possibility that increased central noradrenergic activity serves a role in benzodiazepine withdrawal similar to the role hypothesized for noradrenergic activity in opiate withdrawal.

Animals↗

Substance K and substance P differentially modulate mesolimbic and mesocortical systems.

The newly discovered peptide substance K (SK) is an aliphatic tachykinin structurally related to the aromatic tachykinin substance P (SP). Immunohistochemical examination showed a close association between SK afferents and dopamine (DA) cell bodies. Examination of the possible role of SK in modulating midbrain DA systems revealed that SP, but not SK, is associated with the stress response of the mesocortical system. Ventral tegmental area injections of SK effected locomotor hyperactivity, a mesolimbic-mediated behavior. Ventral tegmental injections of SP, but not SK, activated DA metabolism in the prefrontal cortex, while SK injections altered DA metabolism in the nucleus accumbens, but not the cortical site. These data suggest that SK and SP may differentially modulate the mesolimbic and mesocortical systems.

Animals↗

Dopamine autoreceptor stimulation increases protein carboxyl methylation in striatal slices.

We have investigated the possibility that protein carboxyl methylation is involved in coupling dopamine autoreceptor stimulation to intracellular events such as inhibition of dopamine synthesis or release. The dopamine agonists apomorphine and TL-99 were found to stimulate methyl ester formation in striatal slices preloaded with [3H]methionine. The stimulatory effects of apomorphine were dose-dependent, were not due to changes in [3H]methionine uptake or S-[3H]-adenosylmethionine formation, and were blocked by the stereospecific dopamine antagonist (+)-butaclamol. Stimulation of methyl ester formation by dopamine agonists is readily observed only when slices are prepared from rats pretreated with reserpine to deplete endogenous brain catecholamines. This suggests that in slices prepared from normal rats endogenous dopamine (DA) released during slice preparation and incubation masks the effects produced by exogenously administered dopamine agonists on protein carboxyl methylase (PCM) activity. Additional experiments suggested that the effects of apomorphine were mediated via an interaction with DA autoreceptors rather than with postsynaptic DA receptors. Destruction of monoamine neurons and their associated autoreceptors by injecting 6-hydroxydopamine into the area of the medial forebrain bundle abolished the stimulatory effects of apomorphine on methyl ester formation in striatal slices. Furthermore the putative selective DA autoreceptor agonist EMD 23 448 was also found to stimulate methyl ester formation in striatal slices. These findings, discussed in terms of calcium-dependent functions, support the hypothesis that PCM may be a key component in the biochemical transduction of DA autoreceptor stimulation.

Animals↗

Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity.

The noradrenergic alpha-2 receptor agonist, clonidine, suppresses many of the effects of opiate withdrawal in both humans and other animals and this is consistent with the data indicating important interactions of opiate and noradrenergic systems in brain. This evidence supports the hypothesis that central noradrenergic hyperactivity is involved in the expression of major signs and symptoms of the opiate withdrawal syndrome, but to date clinical studies have not provided biochemical data consistent with this idea. In order to assess whether naltrexone precipitated opiate withdrawal in methadone addicted human subjects is associated with changes in noradrenergic function, a double-blind study was completed in which 15 methadone-dependent subjects received naltrexone and 8 subjects received placebo. Signs and symptoms of the opiate abstinence syndrome increased significantly in the 15 subjects who received naltrexone compared with the 8 who received placebo. Plasma concentrations of free MHPG also increased significantly in those subjects who took naltrexone compared to the placebo treated subjects. In addition, withdrawal signs and symptoms were significantly correlated with plasma MHPG concentration. Since several compounds which suppress central noradrenergic activity also reduce the severity of the withdrawal syndrome, the noradrenergic hyperactivity suggested by the present clinical study may be a functional mechanism for at least part of the opiate withdrawal syndrome.

Adult↗

Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons.

Electrophysiological and biochemical techniques were used to study midbrain dopamine systems. In the electrophysiological studies, projection areas of individual dopaminergic cells were identified by antidromic activation. Dopamine cells which innervate the piriform cortex and those that innervate the caudate nucleus demonstrated their usual dose-dependent inhibitory response to both the intravenous administration of the direct-acting dopamine agonist apomorphine and the microiontophoretic application of dopamine. In contrast, the firing rate of dopamine neurons which project to the prefrontal cortex and of those terminating in the cingulate cortex was not altered by either the intravenous administration of low to moderate doses of apomorphine or microiontophoretically applied dopamine. The mean basal discharge rate and degree of burst firing was also different between these subgroups of midbrain dopaminergic neurons. Mesoprefrontal and mesocingulate dopamine neurons had mean firing rates of 9.3 and 5.9 spikes/s respectively, and showed intense burst activity. Mesopiriform and nigrostriatal dopamine cells had discharge rates of 4.3 and 3.1 spikes/s and displayed only moderate bursting. The dopaminergic nature of those mesocortical neurons insensitive to apomorphine and dopamine was confirmed using combined intracellular recording and catecholamine histofluorescence techniques. Thus, after the intracellular injection of colchicine and subsequent processing for glyoxylic acid-induced histofluorescence, the injected cells could be identified by their brighter fluorescences compared to the surrounding, normally fluorescing, non-injected dopamine neurons. Using biochemical techniques, subgroups of midbrain dopaminergic systems were again found to differ. The administration of gamma-butyrolactone increased dopamine levels in all areas sampled (prefrontal, cingulate and piriform cortices as well as the caudate nucleus). However, although this effect was readily reversed in both the piriform cortex and caudate nucleus by pretreatment with apomorphine, this treatment had no effect on the increased dopamine levels observed in the prefrontal and cingulate cortices. In addition, the decline in dopamine levels after synthesis inhibition with alpha-methyltyrosine was significantly faster in the prefrontal and cingulate cortices relative to the caudate nucleus. The piriform cortex showed an intermediate decline which was not significantly different from that observed in any of the other regions.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

Pharmacology of dopamine neurons innervating the prefrontal, cingulate and piriform cortices.

The pharmacology of a number of distinct dopamine (DA) systems was studied. Those DA projections possessing autoreceptors (striatum, olfactory tubercle and piriform cortex) exhibited large changes in DA metabolism in response to systemic administration of DA agonists and antagonists. In contrast, in those DA systems which lack autoreceptors (the prefrontal and cingulate cortical innervations) little or no response to DA agonists and a diminished response to DA antagonists was seen. When DA metabolism was inhibited by administration of a MAO inhibitor, reductions in HVA were observed in all brain regions studied. DA turnover appeared faster in the prefrontal and cingulate cortices than in the DA systems possessing autoreceptors.

3,4-Dihydroxyphenylacetic Acid↗